

POSTER PRESENTATION

Open Access

Enhancing natriuretic peptide bioactivity prevents bleomycin-induced pulmonary fibrosis

Reshma S Baliga^{1*}, Sarah L Trinder¹, Christopher J Scotton², Rachel C Chambers², Raymond J MacAllister³, Adrian J Hobbs^{1,3}

From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Halle, Germany. 24-26 June 2011

Background

Idiopathic pulmonary fibrosis (IPF) is a progressive fibro-proliferative disorder of unknown etiology, with no effective treatment regimen, and a median survival of just 3–5 years following diagnosis [1]. Pulmonary Hypertension (PH) often complicates IPF and is associated with higher mortality. Augmentation of endogenous natriuretic peptide (NP) stimulated cGMP, using a neutral endopeptidase inhibitor (NEPi) in combination with a phosphodiesterase 5 inhibitor (PDE5i), synergistically prevents pathogenesis in a hypoxic model of PH [2]. Herein, we assessed the efficacy of this novel NEPi/PDE5i combination therapy in a model of pulmonary fibrosis.

Methods

Littermate wild-type (WT) and NP receptor-A knockout (NPR-A KO) mice (male; 20-25g; C57BLK6 background) were instilled with saline (control) or Bleomycin (Bleo; 1mg/kg) in the absence or presence of the PDE5i sildenafil (30mg/kg/day; p.o.) or the NEPi ecdotril (60mg/kg/day; p.o.). Haemodynamic and morphological parameters were measured 14 days post Bleo administration.

Results

Bleo treatment caused a significant rise in right ventricular systolic pressure (RSVP) in WT mice that was not reduced by either sildenafil or ecdotril alone, but significantly inhibited by the combination (Figure 1). Bleo administration also resulted in right ventricular

hypertrophy (RVH); this was prevented by treatment with sildenafil, ecdotril or the combination (RV/LV+S; Control: 0.2486±0.005, Bleo: 0.3054±0.0177, Bleo+sildenafil: 0.258±0.006*, Bleo+ecdotril: 0.261±0.008*, Bleo+combination: 0.247±0.008*; **P*<0.05 versus Bleo).

Bleo instillation enhanced total lung collagen accumulation (index of fibrosis) which was ameliorated by concomitant administration of sildenafil, ecdotril or the combination (Control: 1.692±0.2, Bleo: 4.4±0.35, Bleo+combination: 2.124±0.12*; **P*<0.05 versus Bleo).

NPR-A KO mice, lacking the bioactivity of ANP and BNP, exhibited an exaggerated haemodynamic response to Bleo (WT Bleo RSVP: 31.77±1.96mmHg, KO Bleo RSVP: 41.68±2.78mmHg; *P*<0.05), and the beneficial effects of the combination therapy were lost (KO Bleo+combination RSVP: 39.84±2.41mmHg; *P*>0.05 versus KO Bleo). A similar loss in efficacy of the combination treatment was observed against RVH (KO Bleo RV/LV+S: 0.252±0.008, KO Bleo+combination RV/LV+S: 0.234±0.017; *P*>0.05). Figure 1.

Conclusion

The NEPi/PDE5i combination is effective in ameliorating both the haemodynamic aberrations and fibrotic lung disease in this model. This beneficial pharmacodynamic activity depends on the bioactivity of NPs, which represent an endogenous protective mechanism limiting disease progression. This work substantiates the therapeutic potential of manipulating NP and cyclic GMP signalling for PH and IPF.

* Correspondence: r.baliga@ucl.ac.uk

¹Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, UK

Full list of author information is available at the end of the article




Figure 1 Right ventricular systolic pressure (RVSP) in saline-treated mice (n=14), and Bleo-treated (n=8) animals in the absence and presence of sildenafil (SILD, n=7), ecdotril (ECAD; n=8) and combination treatment (n=9). * $P < 0.05$ versus Bleo alone.

doi:10.1186/1471-2210-11-S1-P3

Cite this article as: Baliga et al.: Enhancing natriuretic peptide bioactivity prevents bleomycin-induced pulmonary fibrosis. *BMC Pharmacology* 2011 **11**(Suppl 1):P3.

Author details

¹Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, UK. ²Centre for Respiratory Research, University College London, Gower Street, London WC1E 6BT, UK. ³Centre for Clinical Pharmacology, University College London, Gower Street, London WC1E 6BT, UK.

Published: 1 August 2011

References

1. Eickelberg O, Selman M: Update in diffuse parenchymal lung disease 2009. *Am J Respir Crit Care Med* 2010, **181**:883-888.
2. Baliga RS, Zhao L, Madhani M, Lopez-Torondel B, Visintin C, Selwood D, et al: Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2008, **178**:861-869.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

 BioMed Central